Search

everythinglearnresearchcommunity

for

Search:↓

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Ruxolitinib can help regrow hair in severe alopecia areata.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Reducing gefitinib dosage improved hair loss, but scarring remained.

JAK inhibitors show promise for treating various skin diseases.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

The combination treatment showed a higher response rate but no significant survival benefits.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.